Hong Kong SAR

Asia’s third online-only IPO was launched this week, confirming that virtual roadshows are a new normal for the region’s equity capital markets amid the Covid-19 pandemic. Companies elsewhere should take heed.

Akesobio, a Chinese biopharmaceutical firm, has launched an online-only roadshow for its up to HK$2.58bn ($332.9m) IPO amid numerous country-wide lockdowns globally to combat the Covid-19 coronavirus pandemic.

German agency L-Bank steamed into the dim sum bond market on Tuesday to print what could be the start of a new flurry of offshore renminbi issuance.

US-listed AMTD International floated on the Singapore Exchange this week, debuting dual-class shares on the southeast Asian bourse through a secondary offering.

WeDoctor, a Chinese healthcare app, has added Citi to the syndicate team of its Hong Kong IPO, GlobalCapital Asia understands.

Veteran capital markets banker Richard Taylor has left CLSA after more than two decades at the boutique investment bank.

Chinese biopharmaceuticals firm Akesobio is preparing to launch bookbuilding for its IPO next week, according to a source close to the deal.

The government’s response to the coronavirus has forced me to spend more time at home. Unfortunately, my wife is doing the same thing.

DBS’s former head of North Asia loan distribution and origination is set to join China Citic Bank International, according to multiple sources aware of the move.

Zhejiang Geely Holding Group, a Chinese auto company, is in talks with banks for a new loan to support a planned restructuring.

Chinese biopharmaceutical firm Akesobio has got the greenlight from the Hong Kong Stock Exchange for its IPO, which is expected to raise $200m to $300m, according to a source familiar with the matter.

Hong Kong-listed Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has won approval from Shanghai’s bourse to list shares on the Star board.